SCHEMBL25368352

SCHEMBL25368352

COc1c(F)cc(CO)c(F)c1F

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
PDE4A P27815 3/20 0.39
PDE4B Q07343 3/20 0.39
PDE4C Q08493 3/20 0.39
PDE4D Q08499 3/20 0.39
MEP1B Q16820 1/20 0.35
CYP19A1 P11511 1/20 0.33
PDE5A O76074 2/20 0.33
PDE1A P54750 2/20 0.33
PDE1B Q01064 2/20 0.33
PDE3B Q13370 2/20 0.33
PDE1C Q14123 2/20 0.33
PDE3A Q14432 2/20 0.33
CA2 P00918 1/20 0.31
CA4 P22748 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
TUBB1 Q9H4B7 3/20 0.31
DBH P09172 1/20 0.31
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12560589 0.84 MAPT (0.42) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL25364956 0.82 PDE4A (0.32) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL3932880 0.80 MEP1B (0.35) MEP1BCYP19A1TUBB1DBH
SCHEMBL18394008 0.78 MAPT (0.41) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL718130 0.78 CYP1A2 (0.47)
SCHEMBL1940273 0.76 MAPT (0.46) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL8470910 0.76 MEP1B (0.51) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL22802449 0.75 SQOR (0.36) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL29490411 0.75 SQOR (0.36) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL27828906 0.75 POLB (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083853-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, INC. 2024-03-14 US disclosed
CN-116600801-A HSD17B13 inhibitors and uses thereof FL2022-001公司 2023-08-15 CN disclosed
EP-4221701-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, Inc. (US) 2023-08-09 EP disclosed
WO-2022072491-A1 HSD17B13 INHIBITORS AND USES THEREOF METACRINE, INC. (US) 2022-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083853-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B11, HSD17B1 MAPT 2694/4885PDE4A 890/4885PDE4B 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.